Technical Analysis for LPCN - Lipocine Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Flat | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 8.28% | |
Wide Bands | Range Expansion | 8.28% | |
Oversold Stochastic | Weakness | 8.28% | |
Inside Day | Range Contraction | 7.14% | |
Wide Bands | Range Expansion | 7.14% | |
Oversold Stochastic | Weakness | 7.14% | |
MACD Bearish Centerline Cross | Bearish | 8.05% | |
Stochastic Reached Oversold | Weakness | 8.05% | |
Lower Bollinger Band Touch | Weakness | 8.05% | |
Oversold Stochastic | Weakness | 8.05% |
Alert | Time |
---|---|
Rose Above 50 DMA | 7 minutes ago |
10 DMA Resistance | about 1 hour ago |
Rose Above Previous Day's High | about 2 hours ago |
Up 5% | about 2 hours ago |
Rose Above 10 DMA | about 3 hours ago |
Get a Trading Assistant
- Earnings date: 11/06/2024
Lipocine Inc. Description
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Alcohol Pharmaceutical Products Gastrointestinal Clinical Research Clinical Trial Metabolism Bypass Ketones Testosterone Androstanes Preterm Birth
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.79 |
52 Week Low | 2.38 |
Average Volume | 32,561 |
200-Day Moving Average | 5.28 |
50-Day Moving Average | 5.08 |
20-Day Moving Average | 5.39 |
10-Day Moving Average | 5.03 |
Average True Range | 0.46 |
RSI (14) | 41.18 |
ADX | 27.62 |
+DI | 11.30 |
-DI | 17.86 |
Chandelier Exit (Long, 3 ATRs) | 4.79 |
Chandelier Exit (Short, 3 ATRs) | 6.01 |
Upper Bollinger Bands | 6.30 |
Lower Bollinger Band | 4.49 |
Percent B (%b) | 0.12 |
BandWidth | 33.59 |
MACD Line | -0.10 |
MACD Signal Line | 0.03 |
MACD Histogram | -0.13 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.22 | ||||
Resistance 3 (R3) | 5.26 | 5.12 | 5.14 | ||
Resistance 2 (R2) | 5.12 | 4.99 | 5.10 | 5.11 | |
Resistance 1 (R1) | 4.91 | 4.91 | 4.85 | 4.88 | 5.08 |
Pivot Point | 4.78 | 4.78 | 4.74 | 4.76 | 4.78 |
Support 1 (S1) | 4.57 | 4.65 | 4.50 | 4.54 | 4.34 |
Support 2 (S2) | 4.43 | 4.56 | 4.42 | 4.31 | |
Support 3 (S3) | 4.23 | 4.43 | 4.28 | ||
Support 4 (S4) | 4.20 |